Display options
Cite
Huzarski T, Górecka-Szyld B, Huzarska J, et al. Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hered Cancer Clin Pract. 2017;15:4doi: 10.1186/s13053-017-0064-y.
Huzarski, T., Górecka-Szyld, B., Huzarska, J., Psut-Muszyńska, G., Wilk, G., Sibilski, R., Cybulski, C., Kozak-Klonowska, B., Siołek, M., Kilar, E., Czudowska, D., Janiszewska, H., Godlewski, D., Mackiewicz, A., Jarkiewicz-Tretyn, J., Szabo-Moskal, J., Gronwald, J., Lubiński, J., Narod, S. A. (2017). Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hereditary cancer in clinical practice, 154. https://doi.org/10.1186/s13053-017-0064-y
Huzarski, Tomasz, et al. "Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer." Hereditary cancer in clinical practice vol. 15 (2017): 4. doi: https://doi.org/10.1186/s13053-017-0064-y
Huzarski T, Górecka-Szyld B, Huzarska J, Psut-Muszyńska G, Wilk G, Sibilski R, Cybulski C, Kozak-Klonowska B, Siołek M, Kilar E, Czudowska D, Janiszewska H, Godlewski D, Mackiewicz A, Jarkiewicz-Tretyn J, Szabo-Moskal J, Gronwald J, Lubiński J, Narod SA. Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hered Cancer Clin Pract. 2017 Mar 01;15:4. doi: 10.1186/s13053-017-0064-y. eCollection 2017. PMID: 28265306; PMCID: PMC5333437.
Copy Download .nbib Format: NLM
Share it on

Hered Cancer Clin Pract. 2017 Mar 01;15:4. doi: 10.1186/s13053-017-0064-y. eCollection 2017.

Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer.

Hereditary cancer in clinical practice

Tomasz Huzarski, Barbara Górecka-Szyld, Jowita Huzarska, Grażyna Psut-Muszyńska, Grażyna Wilk, Robert Sibilski, Cezary Cybulski, Beata Kozak-Klonowska, Monika Siołek, Ewa Kilar, Dorota Czudowska, Hanna Janiszewska, Dariusz Godlewski, Andrzej Mackiewicz, Joanna Jarkiewicz-Tretyn, Jadwiga Szabo-Moskal, Jacek Gronwald, Jan Lubiński, Steven A Narod,

Affiliations

  1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  2. Department of Radiology, Pomeranian Medical University, Szczecin, Poland.
  3. Euro-Medic Diagnostics Poland Ltd, Szczecin, Poland.
  4. Oncology Diagnostic Center, Zielona Góra, Poland.
  5. Regional Oncology Center, Kielce, Poland.
  6. Department of Oncology, District Specialist Hospital, ?widnica, Poland.
  7. Oncology Diagnostic Center, Legnica, Poland.
  8. Department of Clinical Genetics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
  9. Prophylactic and Epidemiology Cancer Center, Pozna?, Poland.
  10. Department of Cancer Immunology, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Pozna?, Poland.
  11. District Specialist Hospital, Toru?, Poland.
  12. Department of Radiology, Regional Oncology Hospital, Bydgoszcz, Poland.
  13. Women's College Research Institute, Women's College Hospital and the University of Toronto, 76 Grenville Street, 6th Floor, Toronto, ON M5S 1B2 Canada.

PMID: 28265306 PMCID: PMC5333437 DOI: 10.1186/s13053-017-0064-y

Abstract

BACKGROUND: The addition of MRI to mammography and ultrasound for breast cancer screening has been shown to improve screening sensitivity for high risk women, but there is little data to date for women at average or intermediate risk.

METHODS: Two thousand nine hundred and ninety-five women, aged 40 to 65 years with no previous history of breast cancer were enrolled in a screening program, which consisted of two rounds of MRI, ultrasound and mammography, one year apart. Three hundred and fifty-six women had a

RESULTS: Twenty-seven invasive epithelial cancers, one angiosarcoma and six cases of DCIS were identified over the four-year period. Of the 27 invasive cancers, 20 were screen-detected, 2 were interval cancers, and five cancers were identified in the second or third follow-up year (i.e., after the end of the screening period). For invasive cancer, the sensitivity of MRI was 86%, the sensitivity of ultrasound was 59% and the sensitivity of mammography was 50%. The number of biopsies incurred by MRI (

CONCLUSIONS: In terms of sensitivity, MRI is slightly better than the combination of mammography and ultrasound for screening of women at average or intermediate risk of breast cancer. However, because of additional costs incurred by MRI screening, and the small gain in sensitivity, MRI screening is probably not warranted outside of high-risk populations.

Keywords: Breast cancer; CHEK2; Magnetic resonance imaging; Mammography; Screening; Ultrasound

References

  1. Radiology. 1999 Jun;211(3):845-50 - PubMed
  2. BMJ. 2014 Feb 11;348:g366 - PubMed
  3. Clin Genet. 2009 Jan;75(1):72-8 - PubMed
  4. N Engl J Med. 2004 Jul 29;351(5):427-37 - PubMed
  5. Cancer. 2005 May 1;103(9):1898-905 - PubMed
  6. J Clin Oncol. 2011 Oct 1;29(28):3747-52 - PubMed
  7. JAMA. 2004 Sep 15;292(11):1317-25 - PubMed
  8. J Clin Oncol. 2005 Nov 20;23(33):8469-76 - PubMed
  9. Lancet. 2005 May 21-27;365(9473):1769-78 - PubMed
  10. Br J Cancer. 2012 Jun 26;107(1):24-30 - PubMed
  11. Int J Cancer. 2004 Jul 10;110(5):683-6 - PubMed
  12. J Clin Oncol. 2010 Dec 20;28(36):5265-73 - PubMed
  13. Radiology. 2007 Mar;242(3):698-715 - PubMed
  14. J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 - PubMed
  15. Radiology. 2007 Aug;244(2):381-8 - PubMed
  16. Breast. 2007 Aug;16(4):367-74 - PubMed
  17. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34 - PubMed

Publication Types